DT-9081: Orally Bioavailable EP4 Receptor Antagonist Reaches Clinical Testing in Solid Tumors
- The EP4 receptor (EP4R), a prostaglandin E2 receptor subtype, is a promising immuno-oncology target because its signaling dampens antitumor immunity and drives tumor-associated inflammation.
- A scaffold hopping strategy moved medicinal chemists away from earlier EP4R antagonist chemotypes to a novel chemical series with improved potency and pharmacokinetics.
- Structure-activity relationship (SAR) studies then guided lead optimization, balancing target potency, selectivity, and drug-like properties.
- This process yielded DT-9081, an orally bioavailable small-molecule EP4R antagonist combining potent receptor antagonism, favorable ADME properties, and a clean preclinical safety profile.
- In vitro and in vivo pharmacology data support DT-9081's ability to modulate tumor immunity, and the compound has already completed a Phase I monotherapy trial in patients with solid cancers.
💡 Points
Finally, the paper behind the registry entry. Scaffold hopping off the earlier EP4 chemotypes almost certainly means they were fighting a liability — hERG, metabolic soft spot, take your pick — in the first series; jumping cores is usually the tell that a fix, not a patch, was needed. What's striking is the pace: hit-to-Phase-I told in one publication reads as a genuinely tractable SAR, not a rescue job. The harder sell is mechanism — EP4 antagonism doesn't kill tumor cells directly, it pulls the brake off PGE2-driven immune suppression, so efficacy will live or die on combination data, not monotherapy shrinkage. Worth tracking how DT-9081's selectivity stacks up against the other EP4 antagonists already in the clinic.